Log in to your Inderes Free account to see all free content on this page.
Devyser Diagnostics
111.5 SEK -1.33%1 investor is following this company
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Revenue
169.3M
EBIT %
-34.79 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
DVYSR
Daily low / high price
111 / 116.5
SEK
Market cap
1.82B SEK
Turnover
4.72M SEK
Volume
42K
Latest videos
Financial calendar
Interim report
23.07.2024
Interim report
30.10.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Rutger Arnhult, via bolag | 24.2 % | 24.2 % |
Nordnet Pensionsförsäkringar | 8.3 % | 8.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Devyser Diagnostics, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/9bb34f53-cefc-4dd5-9146-2b3edff3a4ef.png)
Devyser Diagnostics, Audiocast with teleconference, Q2'24
Devyser announces expanded commercial agreement with Thermo Fisher Scientific for post-transplant monitoring NGS products
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Devyser launches updated Y-Chromosomal microdeletion test
Devyser wins all-time high tender for up to 75 MSEK
Devyser wins tender for oncology NGS solutions in Italy
Devyser wins tender for thalassemia in Italy
Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 14 May 2024
Redeye: Devyser Diagnostics Q1 - The recognition of Devyser begins
![Devyser Diagnostics, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/718da6a2-f2c7-4c50-9abc-0d9e03369b7d.png)
Devyser Diagnostics, Audiocast with teleconference, Q1, 2024
Devyser Diagnostics AB publishes quarterly report for the period January to March 2024
Invitation to audiocast for Devyser’s Q1 report 2024
Devyser receives IVDR approval for post-transplant monitoring software
Devyser partners with Hamilton to automate laboratory NGS workflows
Devyser receives MDSAP certification for Brazil
Devyser publishes annual report for 2023
![Devyser Diagnostics, Investor Day, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/21b47d5a-36cd-42ea-85d3-3c9f191b7cde.png)
Devyser Diagnostics, Investor Day, 2024
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
![Devyser Diagnostics, Investor Day, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/3144bca0-5ce1-41b8-ac96-9e65e01d1b15.png)